Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Tandem Diabetes Care (TNDM) Operating Expenses (2016 - 2025)

Tandem Diabetes Care's Operating Expenses history spans 13 years, with the latest figure at $159.2 million for Q4 2025.

  • For Q4 2025, Operating Expenses rose 0.72% year-over-year to $159.2 million; the TTM value through Dec 2025 reached $733.3 million, up 24.56%, while the annual FY2025 figure was $733.3 million, 24.56% up from the prior year.
  • Operating Expenses reached $159.2 million in Q4 2025 per TNDM's latest filing, up from $157.2 million in the prior quarter.
  • In the past five years, Operating Expenses ranged from a high of $239.3 million in Q1 2025 to a low of $76.5 million in Q1 2021.
  • Average Operating Expenses over 5 years is $139.1 million, with a median of $138.4 million recorded in 2023.
  • Peak YoY movement for Operating Expenses: skyrocketed 97.99% in 2023, then tumbled 35.29% in 2024.
  • A 5-year view of Operating Expenses shows it stood at $101.0 million in 2021, then skyrocketed by 31.99% to $133.3 million in 2022, then decreased by 3.71% to $128.4 million in 2023, then rose by 23.12% to $158.0 million in 2024, then rose by 0.72% to $159.2 million in 2025.
  • Per Business Quant, the three most recent readings for TNDM's Operating Expenses are $159.2 million (Q4 2025), $157.2 million (Q3 2025), and $177.7 million (Q2 2025).